Colorectal cancer metastatic
Not recruitingStudy of Pembrolizumab and Temozolomide for Patients with Metastatic Colorectal Cancer Who Have Not Responded to Standard Treatments
Study of Pembrolizumab and Temozolomide for Patients with Metastatic Colorectal Cancer Who Have Not Responded to Standard Treatments
- Disease:Colorectal cancer metastatic
- Substances:PembrolizumabTemozolomide
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets









